MedPath
HSA Approval

MALTOFER SYRUP 50mg/5ml

SIN05700P

MALTOFER SYRUP 50mg/5ml

MALTOFER SYRUP 50mg/5ml

April 8, 1991

VIFOR PHARMA ASIA PACIFIC PTE. LTD.

VIFOR PHARMA ASIA PACIFIC PTE. LTD.

Regulatory Information

VIFOR PHARMA ASIA PACIFIC PTE. LTD.

VIFOR PHARMA ASIA PACIFIC PTE. LTD.

Therapeutic

General Sale List

Formulation Information

SYRUP

**Posology** Dosage and duration of therapy are dependent upon the extent of iron deficiency. Iron deficiency anaemia: the therapy takes about 3–5 months until a normalisation of the haemoglobin value is achieved. Afterwards the therapy should be continued for several weeks, or for pregnant women, at least until the end of the pregnancy with a dosage such as described for iron deficiency without anaemia in order to replenish the iron stores. Iron deficiency without anaemia: the therapy takes about 1–2 months. ![Maltofer Syrup Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/85287718ee1ce81f0e99ffc6a50e301d.png) **Method of administration** The daily dosage can be divided into separate doses or can be taken all at one time. Maltofer® syrup should be taken during or immediately after a meal. Maltofer® syrup can be mixed with fruit and vegetable juices or with bottle-feed. The slight discolouration of the mixture does not affect either the efficacy of the product nor the taste of the drink to which it is added. The supplied measuring cup is used for an exact administration of the dosage.

ORAL

Medical Information

**Therapeutic indications** Treatment of iron deficiency without anaemia and iron deficiency anaemia. Prophylactic therapy of iron deficiency during pregnancy.

**Contraindications** - Known hypersensitivity or intolerance to iron(III)-hydroxide polymaltose complex or any of the excipients - Iron overload (e.g. haemochromatosis, haemosiderosis) - Disturbances in iron utilisation (e.g. anaemia from lead-poisoning, sidero-achrestic anaemia, thalassaemia) - Anaemia not caused by iron deficiency (e.g. haemolytic anaemia or megaloblastic anaemia due to vitamin B12 deficiency).

B03AB05

ferric oxide polymaltose complexes

Manufacturer Information

VIFOR PHARMA ASIA PACIFIC PTE. LTD.

Vifor SA

Active Ingredients

HYDROXIDE POLYMALTOSE COMPLEX EQV IRON

50mg/5ml

Iron

Documents

Package Inserts

Maltofer Syrup PI.pdf

Approved: September 21, 2020

Download
© Copyright 2025. All Rights Reserved by MedPath